PH Roundtable:

Advances in Pulmonary Hypertension

White, RJ et al. PH Roundtable: Imatinib: A Perspecive on Its Potential for PAH Patients.Advances in Pulmonary Hypertension¹ 

关键词: Cardiology;    Rheumatology;    Psychosocial Issues;    WHO Group 1- Pulmonary Arterial Hypertension;    WHO Group 2- PH owing to left heart disease (left heart failure);    PH Medications;    Potential Therapies;    symptoms;    Research;    BMPR2;    Associated Diseases;    Connective Tissue Diseases;    Systolic dysfunction;    Oral therapy;    Phosphodiesterase Inhibitors (PDE-5 Inhibitors);    nitric oxide;    Anticoagulation;    Tyrosine Kinase Inhibitors;    RV Size;    Indicators of diastolic dysfunction;    Non-invasive estimate of PVR;    Pulmonary vascular resistance;    Cardiac Index;    Fick;    Thermodilution;    exercise hemodynamic testing;    vascular remodeling;    endothelial proliferation;    endothelial dysfunction;    angiogenesis;    tricuspid regurgitation;    edema;    patient-reported outcomes;    Drug development;    clinical trial endpoints;    Side Effects;    von Willebr;    Factor;    pre-clinical research;    Medical Membership Network;    CME;    Classification;    Epidemiology;    Screening;   

DOI  :  

学科分类：医学（综合）

来源: Pulmonary Hypertension Association

【 摘 要 】

We invited 4 experts to a telephone roundtable facilitated by guest editor Jim White, MD, PhD, on April13, 2012, to discuss the results of the recent Phase III trial, the Imatinib in Pulmonary ArterialHypertension (IMPRES) trial (NCT00902174). Investigators enrolled patients with pulmonary arterialhypertension with severe hemodynamic impairment at catheterization despite treatment with 2 backgroundtherapies. Patients were randomized to placebo or 200 mg imatinib twice daily for 6 months oftherapy to assess efficacy. Participating in the discussion were Mardi Gomberg-Maitland, MD, MSc,Associate Professor of Medicine and Director, Pulmonary Hypertension Center, University of Chicago;Iona Preston, MD, Co-director, Pulmonary Hypertension Center, Tufts University Medical Center, Boston;Jeremy Feldman, MD, Director, Pulmonary Hypertension Program, Medical Director of Research,Arizona Pulmonary Specialists, Phoenix; Stephen Mathai, MD, MHS, Assistant Professor of Medicine,The Johns Hopkins School of Medicine, Baltimore.

【 授权许可】

All Rights reserved